RxDoctor Payments Data

Eleanor Hardy, PA

Physician Assistant · Charleston, SCNPI 1962172668

Payments from drug & device makers

$1,069in general payments, 2019–2025

Across 17 payments — averaging $62.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$255
  • Lilly USA, LLC$187
  • Mirati Therapeutics, Inc.$161
  • Johnson & Johnson$137
  • Takeda Pharmaceuticals U.S.A., Inc.$124
  • Daiichi Sankyo Inc.$105
  • plus $100 from 2 others

What the payments were for

  • Food & beverage$94789%
  • Education$12211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,069 in reported general payments places this provider in the 65th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$39,023
Medicare patients
139
Services billed
778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate55$856,557
LorbrenaLorlatinib25$496,836
LumakrasSotorasib24$391,334
RetevmoSelpercatinib11$146,282
EliquisApixaban46$29,966
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,172
Oxycodone Hcl75$1,120
Morphine Sulfate17$1,002
Dexamethasone31$481
Morphine Sulfate ErMorphine Sulfate12$449
Ondansetron Hcl34$426
Gabapentin41$408
Mirtazapine26$396
Rosuvastatin Calcium11$298
Prochlorperazine Maleate27$260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$255$856,55755 claims
Lilly USA, LLCRetevmo$187$146,28211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →